Heidelberg Pharma AG (FSE: HPHA) and its partner Huadong Medicine Co., Ltd. have received Clinical Trial Approval from China's National Medical Products Administration (NMPA) for a Phase Ib/II study evaluating pamlectabart tismanitin (HDP-101) in combination regimens for relapsed/refractory multiple myeloma. The approval, announced August 26, 2026, allows the companies to assess the safety, tolerability, and preliminary efficacy of the BCMA-targeting antibody-drug conjugate (ADC) when combined with either pomalidomide and dexamethasone or daratumumab and dexamethasone in adult patients who have received at least one prior line of therapy.
This development is a critical component of Heidelberg Pharma's strategy to integrate HDP-101 into established treatment protocols, potentially broadening its use to earlier lines of therapy and larger patient populations. By exploring combination approaches, the company aims to enhance the therapeutic index of the ADC, which has already demonstrated promise as a monotherapy in an ongoing Phase I/IIa trial in the U.S. and Europe since 2022. After determining the recommended Phase II dose, a monotherapy bridging study was launched in China in March 2026, laying the groundwork for the newly approved combination trial.
HDP-101 has received significant regulatory recognition from the U.S. Food and Drug Administration, including Orphan Drug Designation in March 2024 and Fast Track Designation in October 2025. These designations underscore the potential of the drug to address unmet medical needs in multiple myeloma, a disease that remains incurable for many patients despite advances in treatment.
The partnership between Heidelberg Pharma and Huadong Medicine dates back to February 2022, when the companies entered into a strategic agreement that included an equity investment. Under this deal, Huadong Medicine obtained exclusive development and commercialization rights to HDP-101 across 20 Asian markets and became the second-largest shareholder of Heidelberg Pharma. This collaboration leverages Huadong's regional expertise and resources, with the Chinese partner bearing the development costs for the trial.
Heidelberg Pharma is distinguished by its use of amanitin, a toxin derived from the death cap mushroom, in its proprietary ATAC technology. This innovative approach represents a new modality in cancer therapy, differentiating the company's ADC pipeline. Beyond HDP-101, the company is advancing HDP-102 for Non-Hodgkin Lymphoma and has preclinical programs targeting other solid tumors, which are available for partnering.
The approval of the combination trial in China is a strategic move that could accelerate the clinical development of HDP-101 and potentially lead to new treatment options for multiple myeloma patients in Asia and globally. For the biotech industry, this highlights the growing importance of regional partnerships in advancing oncology therapeutics and the value of exploring combination regimens to fully realize the potential of novel drug candidates.
